If chemotherapy is still going to be used for another decade, there needs to be continued research into it and how to improve quality of life for patients treated with it, said Bruce Feinberg, DO, vice president and chief medical officer of Cardinal Health Specialty Solutions.
If chemotherapy is still going to be used for another decade, there needs to be continued research into it and how to improve quality of life for patients treated with it, said Bruce Feinberg, DO, vice president and chief medical officer of Cardinal Health Specialty Solutions.
In what ways can chemotherapy be improved upon with additional research?
So, it raises questions about, if chemotherapy is truly alive and well and the stories about its demise have been exaggerated, then are we past the point of researching chemotherapy? Is the future of research strictly [immuno-oncology] and precision medicine and now gene therapy? Or is there a need, if we’re going to be using chemotherapy for at least a decade to come, to continue that research into better chemotherapy? Chemotherapy that not only has higher efficacy, but significantly better quality of life and adverse event profile.
Do you think there is a future in which chemotherapy eventually is no longer used, or with improvements and new agents will chemotherapy always have some sort of role to play in certain cancers?
So, it’s difficult when you look out at phase 1, 2, and 3 clinical trials and just doing a simple search on ClinicalTrial.gov, and do that in the major cancer types—so, let’s say the top 10 by prevalence—it’s hard to see where the end of chemotherapy really exists. It doesn’t appear to be in the next decade. Could it be a decade later?
So many of the trials that are in design are designed as chemotherapy plus novel mechanism of action drug. And so, it’s a little different than when we focused on chemotherapy only, as we did in our research on single-agent sequential treatment of metastatic breast cancer. But nonetheless, it still suggests that chemotherapy is around for a long time to come.
Increasing Lp(a) Awareness for Better Cardiovascular Health: Dr Mary McGowan
March 24th 2024For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy
March 15th 2024The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.
Read More
Navigating the Mental Health Challenges of Cancer Diagnosis, Treatment, and Survivorship
March 12th 2024Stress has potential links to worse outcomes in cancer, such as decreased quality of life and greater risks of disease progression and metastasis. There is a complex mix of emotions patients with cancer experience.
Read More